News - Pioglitazone


Current filters:


Popular Filters

Merck & Co drops combo diabetes drug Janacti filing in Europe; presents data on discontinued vorapaxar study


The European Medicines Agency says it has been formally notified by Merck Sharp & Dohme (Europe), a subsidiary…

Cardio-vascularDiabetesJanactiMerck & CoPharmaceuticalPioglitazoneRegulationResearchsitagliptinvorapaxar

US FDA sets PUDFA date for Takeda diabetes drug alogliptin and fixed-dose alogliptin/pioglitazone


The US subsidiary of Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) said yesterday…

alogliptinDiabetesNorth AmericaPharmaceuticalPioglitazoneRegulationTakeda Pharmaceuticals

Prior CHMP positive benefit-risk for pioglitazone confirmed; EMA starts NSAIDS review


The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has clarified its…

ActosDiabetesEuropeNeurologicalPharmaceuticalPioglitazoneRegulationTakeda Pharmaceuticals

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top